MSB 12.1% 55.5¢ mesoblast limited

That's my take, more over when you add Remestemcell-L to the...

  1. 3,753 Posts.
    lightbulb Created with Sketch. 1268
    That's my take, more over when you add Remestemcell-L to the available treatments, we would only be treating those with the high MAP. As we already know that these patients have a 90% chance of not responding to steroids. Remestemcell-L will become a first in line treatment in combination with steroids. When we finally get to test the product on adults we do not need to use jak inhibitors, they would be used as a salvage treatment in those remaining few that do not respond to our therapy.

    I would also think it highly likely that MAP biomarkers would be used as a quality attributed between batches.
    As a final check on the product for release we would only need to treat 4 patients to have a 90% confidence that the product was highly effective.

    Good luck all



 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
4 62700 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 40000 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 29/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.